CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men

[1]  R. Hayes,et al.  Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma , 2010, The Prostate.

[2]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[3]  Meilin Wang,et al.  A Six-Nucleotide Insertion-Deletion Polymorphism in the CASP8 Promoter Associated with Risk and Progression of Bladder Cancer , 2009, Clinical Cancer Research.

[4]  P. Radice,et al.  Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases , 2009, Breast Cancer Research and Treatment.

[5]  Emili Montserrat,et al.  Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. , 2008, Cancer research.

[6]  T. Matsuda,et al.  Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. , 2008, Japanese journal of clinical oncology.

[7]  A. Cox,et al.  The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study , 2008, Breast Cancer Research and Treatment.

[8]  Byung-Ho Nam,et al.  Aetiology of cancer in Asia. , 2008, Asian Pacific journal of cancer prevention : APJCP.

[9]  Q. Wei,et al.  A Novel Functional Polymorphism C1797G in the MDM2 Promoter Is Associated with Risk of Bladder Cancer in a Chinese Population , 2008, Clinical Cancer Research.

[10]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[11]  P. Broderick,et al.  CASP8 variants D302H and −652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population , 2008, British Journal of Cancer.

[12]  B. Henderson,et al.  A promoter polymorphism in the CASP8 gene is not associated with cancer risk , 2008, Nature Genetics.

[13]  D. Qiu,et al.  Comparison of time trends in liver cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. , 2007, Japanese journal of clinical oncology.

[14]  Changqing Zeng,et al.  A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers , 2007, Nature Genetics.

[15]  A. Chokkalingam,et al.  Molecular epidemiology of prostate cancer: hormone-related genetic loci. , 2007, Frontiers in bioscience : a journal and virtual library.

[16]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[17]  Dong Sun Kim,et al.  Polymorphisms in the caspase-8 gene and the risk of lung cancer. , 2006, Cancer genetics and cytogenetics.

[18]  R. Siegel.  Caspases at the crossroads of immune-cell life and death , 2006, Nature Reviews Immunology.

[19]  P. Bugert,et al.  Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. , 2006, Carcinogenesis.

[20]  Po-ki Ho,et al.  Mammalian initiator apoptotic caspases , 2005, The FEBS journal.

[21]  H. Sim,et al.  Changing demography of prostate cancer in Asia. , 2005, European journal of cancer.

[22]  H. Yoshida,et al.  [Machinery of programmed cell death]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[23]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[24]  B. Ponder,et al.  Association of a common variant of the CASP8 gene with reduced risk of breast cancer. , 2004, Journal of the National Cancer Institute.

[25]  A. Tsatsoulis,et al.  Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. , 2003, European journal of endocrinology.

[26]  M. Thun,et al.  Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[28]  J. Rehm,et al.  Low-risk Drinking Guidelines: The Scientific Evidence , 1999, Canadian journal of public health = Revue canadienne de sante publique.

[29]  T. Matsuda,et al.  Comparison of time trends in testicular cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. , 2008, Japanese journal of clinical oncology.

[30]  T. Matsuda,et al.  Comparison of time trends in prostate cancer incidence (1973 1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. , 2007, Japanese journal of clinical oncology.

[31]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.